Bladder Cancer Weekly

March 04, 2024

Videos

Peer-to-Peer Clinical Conversations

Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NIMBC and Quantifies Molecular Response to Nadofaragene Firadenovec - Vikram Narayan

Sam Chang hosts Vikram Narayan for a discussion on the potential of urinary markers in predicting responses to nadofaragene, a treatment for BCG-unresponsive bladder cancer.

View

Establishing Nadofaragene Firadenovec in a Large Urology Practice - Daniel Canter

Ashish Kamat and Daniel Canter discuss the role of nadofaragene firadenovec in the treatment of non muscle-invasive bladder cancer.

View

Beyond the Abstracts

Global Meta-Analysis of Urine Microbiome: Colonization of PAH-Degrading Bacteria Among Bladder Cancer Patients - Beyond the Abstract

Association of Age with Non-Muscle-Invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? - Beyond the Abstract

Conference Coverage

Southern CA GU Cancer Research Forum 2024: Bladder Cancer Studies: NMIBC, MIBC, Metastatic First-Line, and Metastatic Salvage

Southern CA GU Cancer Research Forum 2024: Key Updates in Bladder Cancer

ASCO GU 2024: AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma Versus Observation (Late-Breaking Abstract)

Physician-Scientist Review Articles

Clinical Features of Patients with Muscle-Invasive Urothelial Carcinoma Undergoing Radical Resection - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium.

Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology.

Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis.

Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG).

DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.

Lessons from a population-based bladder cancer registry: exploring why survival is not improving.

A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.

Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.

Urine-Based Biomarker Test Uromonitor® in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer-A Systematic Review and Meta-Analysis of Diagnostic Test Performance.

BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
1390 Ione Pass Trail,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login